GTx, Inc. to Present Additional Efficacy and Safety Analyses from the Toremifene 80 mg Phase III ADT Clinical Trial at the Annual Meeting of the American Society for Bone and Mineral Research

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced that additional efficacy and safety analyses from the Phase III clinical trial evaluating toremifene 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) in men with advanced prostate cancer will be presented September 16th in an oral session at the 2008 Annual Meeting of the American Society for Bone and Mineral Research being held in Montreal, Canada.